Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Breast 2

Conditions

Breast Neoplasms 16Stomach Neoplasms 8Rectal Neoplasms 8Colorectal Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Adenocarcinoma Of Esophagus 6Adenocarcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 4Pancreatic Neoplasms 4Esophageal Neoplasms 4Nasopharyngeal Carcinoma 3Esophageal Squamous Cell Carcinoma 2Carcinoma 2Biliary Tract Neoplasms 2Anus Neoplasms 2Advanced Solid Tumour 2Solid Tumors 1Peritoneal Neoplasms 1Neoplasms 1HIV Infections 1HER2-positive Gastric Cancer 1HER2-positive Breast Cancer 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Clinical Stage I Gastric Cancer AJCC v8 1Clinical Stage I Esophageal Adenocarcinoma AJCC v8 1Anal Canal Carcinoma 1

Interventions

pembrolizumab 31Paclitaxel 14Carboplatin 12Cisplatin 8lenvatinib 7Pemetrexed 5olaparib 4belzutifan 4Oxaliplatin 4Fluorouracil 4Docetaxel 4Capecitabine 4patritumab deruxtecan 3Leucovorin 3Gemcitabine 3Bevacizumab 3Albumin-Bound Paclitaxel 3Acetaminophen 3Saline Solution 2Levoleucovorin 2Irinotecan 2Histamine H2 Antagonists 2Histamine Antagonists 2Etoposide 2Dexamethasone 2Cetuximab 2130-nm albumin-bound paclitaxel 2zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × Capecitabine × 30 days × Clear all
NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06312176 2026-05-22

MK-2870-010

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,200 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06966700 2026-05-22

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Merck Sharp & Dohme LLC

Phase 3 Recruiting
2,400 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05152147 2026-05-19

HERIZON-GEA-01

Jazz Pharmaceuticals

Phase 3 Active not recruiting
920 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡